Navigation Links
Gamida Cell and Cellerix Partner on Feasibility Study

JERUSALEM and MADRID, October 21 /PRNewswire/ -- Gamida Cell Ltd. and Cellerix, S.A. announced today that the companies are collaborating on a feasibility study to evaluate the added value of combining the proprietary technologies of each.

Gamida Cell is developing a series of technologies to expand, ex vivo, populations of stem/progenitor cells that display increased in vivo homing and engraftment activities. The company's lead product, StemEx(R), comprised of expanded populations of adult stem cells derived from umbilical cord blood (UCB), is used today as an experimental treatment for blood cancers like leukemia and lymphoma. The Company anticipates StemEx(R) will reach the market in 2011.

Cellerix is developing a new generation of cell-based medicines using expanded adult stem cells (eASCs) obtained from adipose tissue. The Company is also very active developing its allogeneic eASCs platform as 2nd generation products through its Cx611 program for high potential markets. eASCs are a natural medicine with the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a potential revolution in the treatment of some diseases that cannot satisfactorily be cured at present.

"Gamida Cell is enthusiastic about working with Cellerix, a world class company and an industry leader," said Dr. Yael Margolin, president and CEO of Gamida Cell. "Gamida Cell's technologies have demonstrated to improve in vivo functionality of ex-vivo expanded hematopoietic stem cells. This collaboration seeks to evaluate the feasibility of improving clinical efficacy of ex vivo expanded adult stem cells obtained from adipose tissue by means of increasing homing and retention following infusion. The results of this study could lead to an entirely new understanding of the widespread application of our various technologies and expand the number of possibilities for Gamida Cell in terms of product development and partnerships."

"Cellerix has a promising pipeline of cell therapeutics in advanced clinical trials. Existing data shows that Gamida Cell's expansion technologies are very effective in hematopoietic stem cells. Combining the technologies of our companies could lead to developing a new line of cell therapeutics. We are looking forward to seeing the results of this collaboration with an eye on further co-development and commercialization opportunities," said Eduardo Bravo, CEO at Cellerix.

About Cellerix, S.A.

Cellerix is a biopharmaceutical company with a pipeline of late clinical stage cell therapy products (phase II and III) targeting indications that represent a high unmet medical need.

The company has three products undergoing clinical trials: Ontaril(R) (Cx401) for the treatment of complex perianal fistulas, currently in Phase III, first medicine expected to reach the market in 2011, Cx501 a cell therapy product for treating epidermolysis bullosa (EB) currently in Phase II and Cx601 consists of a formulation based on donor cells (allogeneic origin) for treating complex perianal fistulas in Crohn's disease patients now in phase II. Ontaril(R), Cx501 and Cx601 have been designated orphan status by the European Medicines Agency (EMEA). Cellerix has a solid investor base, its ownership structure includes blue chips international VCs and corporate funds from two big pharma companies.

For more information: please visit

About Gamida Cell

Gamida Cell Ltd. is a world leader in stem cell expansion technologies and therapeutic products. The company is developing a pipeline of products in stem cell transplantation and in tissue regeneration to effectively treat debilitating and often fatal illnesses such as cancer, hematological and autoimmune diseases. Gamida Cell's therapeutic candidates contain populations of adult stem cells, selected from non-controversial sources such as umbilical cord blood and bone marrow, which are expanded in culture. Gamida Cell was successful in translating these proprietary expansion technologies into robust and validated manufacturing processes under GMP. Gamida Cell's first product, StemEx(R) for blood cancers, is currently being studied in a pivotal registration trial now enrolling patients at leading stem cell transplant centers worldwide ( Gamida Cell's current shareholders include: Elbit Imaging, Biomedical Investment, Israel Healthcare Venture, Teva Pharmaceuticals, Amgen, Denali Ventures and Auriga Ventures.

    For more information, please visit:

    Press contact for Cellerix:
    Abigail Diaz-Agero
    +34-91-436-1806 or

    Press contact for Gamida Cell:
    Marjie Hadad
    +972-54-536-5220 or

SOURCE Gamida Cell LTD

SOURCE Gamida Cell LTD
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. CryoLife Expands Distribution of Hemostase MPH(R) to France through Laboratoire Gamida
4. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
5. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
6. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
7. GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product
8. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
9. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
10. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
11. NxStage Medical to Present at the Thomas Weisel Partners Healthcare Conference on September 5, 2007
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016  Regular discussions on a range ... place between the two entities said Poloz. Speaking ... Ottawa , he pointed to the country,s inflation ... federal government. "In ... "Both institutions have common economic goals, why not sit down ...
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, into ... for over 35 years, is proud to add Target to its list of ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking ... Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity as ...
Breaking Biology Technology:
(Date:6/9/2016)... -- Perkotek an innovation leader in attendance control systems is proud to announce the introduction ... to make sure the right employees are actually signing in, and to even control ... ... ... ...
(Date:6/2/2016)... , June 2, 2016 The ... has awarded the 44 million US Dollar project, for ... Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... leader in the production and implementation of Identity Management Solutions. ... January, however Decatur was selected for ...
(Date:5/24/2016)... Calif. , May 24, 2016 Ampronix facilitates superior patient care by ... LMD3251MT  3D medical LCD display is the latest premium product recently added to the ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):